Evidence map›Paper›PMID 30367443›Full record

ArticleEndocrine2019

In vitro antitumor activity of progesterone in human adrenocortical carcinoma.

Martina Fragni, Chiara Fiorentini, Elisa Rossini, Simona Fisogni, Sara Vezzoli, Sara A Bonini, Cristina Dalmiglio, Salvatore Grisanti, Guido A M Tiberio, Melanie Claps and 9 more

Registry-linked trialOpen access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Endocrine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05913427 (Prospective, Phase II Study to Evaluate the Efficacy of Addition of Progesterone to Standard Chemotherapy According to Etoposide-Doxorubicin-Cisplatin Scheme Plus Mitotane), which is not on this map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05913427 phase2recruitingnot on this mapstarted 2022, after this paper: background citation

Prospective, Phase II Study to Evaluate the Efficacy of Addition of Progesterone to Standard Chemotherapy According to Etoposide-Doxorubicin-Cisplatin Scheme Plus Mitotane (EDP-M) in Patients With Advanced Adrenocortical Carcinoma (ACC)

TypeinterventionalSponsorAzienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaRan2022 to 2027Enrolled80ConditionsAdrenocortical CarcinomaArmsEtoposide, doxorubicin, cisplatin and Mitotane plus Megestrol Acetate 160 MG, Etoposide, doxorubicin, cisplatin and Mitotane plus Placebo
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 1 country.

Martina FragniSection of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Chiara FiorentiniSection of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Elisa RossiniSection of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Simona FisogniPathology Unit, Department of Molecular and Translational Medicine, University of Brescia and ASST Spedali Civili di Brescia, Brescia, Italy.
Sara VezzoliSection of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Sara A BoniniSection of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Cristina DalmiglioOncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia and ASST Spedali Civili di Brescia, Brescia, Italy.
Salvatore GrisantiOncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia and ASST Spedali Civili di Brescia, Brescia, Italy.
Guido A M TiberioSurgical Clinic, Department of Clinical and Experimental Sciences, University of Brescia and ASST Spedali Civili di Brescia, Brescia, Italy.
Melanie ClapsOncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia and ASST Spedali Civili di Brescia, Brescia, Italy.
Deborah CosentiniOncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia and ASST Spedali Civili di Brescia, Brescia, Italy.
Valentina SalviSection of Oncology and Experimental Immunology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Daniela BosisioSection of Oncology and Experimental Immunology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Massimo TerzoloDepartment of Clinical and Biological Sciences University of Turin, Internal Medicine 1, San Luigi Gonzaga Hospital, Orbassano, Italy.
Cristina MissaleSection of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Fabio FacchettiPathology Unit, Department of Molecular and Translational Medicine, University of Brescia and ASST Spedali Civili di Brescia, Brescia, Italy.
Maurizio MemoSection of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Alfredo BerrutiOncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia and ASST Spedali Civili di Brescia, Brescia, Italy. alfredo.berruti@gmail.com.
Sandra SigalaSection of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
University of Brescia · ITAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · ITOspedale San Luigi Gonzaga · IT

Funding

Associazione Italiana per la Ricerca sul Cancro IG14411Associazione Italiana per la Ricerca sul Cancro IG17678Fondazione Camillo Golgi not applicablePrivate Donations not applicable
6 · The paper itself

Abstract

purposeThe management of patients with adrenocortical carcinoma (ACC) is challenging. As mitotane and chemotherapy show limited efficacy, there is an urgent need to develop therapeutic approaches. The aim of this study was to investigate the antitumor activity of progesterone and explore the molecular mechanisms underlying its cytotoxic effects in the NCI-H295R cell line and primary cell cultures derived from ACC patients.

methodsCell viability, cell cycle, and apoptosis were analyzed in untreated and progesterone-treated ACC cells. The ability of progesterone to affect the Wnt/β-catenin pathway in NCI-H295R cells was investigated by immunofluorescence. Progesterone and mitotane combination experiments were also performed to evaluate their interaction on NCI-H295R cell viability.

resultsWe demonstrated that progesterone exerted a concentration-dependent inhibition of ACC cell viability. Apoptosis was the main mechanism, as demonstrated by a significant increase of apoptosis and cleaved-Caspase-3 levels. Reduction of β-catenin nuclear translocation may contribute to the progesterone cytotoxic effect. The progesterone antineoplastic activity was synergically increased when mitotane was added to the cell culture medium.

conclusionsOur results show that progesterone has antineoplastic activity in ACC cells. The synergistic cytotoxic activity of progesterone with mitotane provides the rationale for testing this combination in a clinical study.

Indexed as

Adrenal Cortex NeoplasmsAdrenocortical CarcinomaAntineoplastic Agents, HormonalApoptosisbeta CateninCell CycleCell Line, TumorDrug Screening Assays, AntitumorDrug SynergismHumansMembrane ProteinsMitotanePrimary Cell CultureProgesteroneProgestinsReceptors, ProgesteroneAntineoplastic Agents, Hormonalbeta CateninMembrane ProteinsMitotanePGRMC1 protein, humanProgesteroneProgestinsReceptors, ProgesteroneAdrenocortical carcinomaCell viabilityProgesteroneProgesterone receptor

Identifiers

PMID30367443
OpenAlexW2898449654

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.